<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Exploring AlphaFold 3 for CD47 Antibody-Antigen Binding Affinity: An Unexpected Discovery of Reverse docking - Health AI Hub</title>
    <meta name="description" content="This study investigates AlphaFold 3's (AF3) potential for predicting CD47 antibody-antigen complex structures and assessing binding affinity, aiming to facilita">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>Exploring AlphaFold 3 for CD47 Antibody-Antigen Binding Affinity: An Unexpected Discovery of Reverse docking</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.14676v1" target="_blank">2511.14676v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-18
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Yiyang Xu, Ziyou Shen, Yanqing Lv, Shutong Tan, Chun Sun, Juan Zhang
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> q-bio.BM
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.14676v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.14676v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This study investigates AlphaFold 3's (AF3) potential for predicting CD47 antibody-antigen complex structures and assessing binding affinity, aiming to facilitate antibody candidate pre-screening in drug development. While AF3 demonstrated promising capabilities for reliable structure and binding energy predictions for most subjects, an unexpected and nonrandom "reverse docking" phenomenon was discovered in a subset of antibodies, attributed to its revolutionary AI model architectures.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research is highly relevant to drug discovery and development, particularly for biologics like antibodies. By leveraging AF3 for accurate structure prediction and binding affinity assessment, the process of identifying and optimizing therapeutic antibody candidates, such as those targeting CD47 for cancer immunotherapy, can be significantly accelerated and made more efficient.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The paper applies AlphaFold 3, an advanced AI model, to accelerate and improve the pre-screening and lead optimization processes for therapeutic antibody candidates. By predicting antibody-antigen binding affinity, the AI assists in identifying potent drug candidates, which is a direct application of AI in drug discovery and therapeutic development for health outcomes. It also contributes to the optimization and design of AI for structural prediction in a biomedical context.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>The study explored AlphaFold 3 (AF3) for predicting structures of CD47 antibody-antigen complexes, a challenging task due to limited crystallographic data.</li>
                    
                    <li>A primary goal was to evaluate AF3's utility in pre-screening potent antibody candidates through binding affinity analysis, comparing its performance to commercial molecular docking software.</li>
                    
                    <li>AF3 proved to be a very promising tool, efficiently producing highly reliable molecular structures and subsequent binding energy predictions for the majority of subjects.</li>
                    
                    <li>An unexpected and nonrandom phenomenon termed "reverse docking" was observed for two specific antibody subjects, indicating a novel issue with AF3's advanced AI architecture.</li>
                    
                    <li>Error correction experiments confirmed that this "reverse docking" phenomenon is likely caused by the revolutionary AI model architectures underlying AF3.</li>
                    
                    <li>The findings offer crucial experience and guidance for the optimization and design direction of future AI models for structural prediction.</li>
                    
                    <li>The authors suggest AF3's potential extends beyond antibody-antigen binding to predict other chemical or physical properties of diverse drug candidates.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study utilized AlphaFold 3 for predicting the structures of CD47 antibody-antigen complexes. Binding affinity analysis was subsequently performed on these predicted structures, and the results were compared against those obtained from established molecular docking modules of commercial software. Error correction experiments were also conducted to analyze and understand the observed "reverse docking" phenomenon.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>AlphaFold 3 demonstrated significant promise in generating highly reliable molecular structures and accurate binding energy predictions for most antibody-antigen subjects. However, an unexpected and nonrandom "reverse docking" phenomenon was identified for a subset of antibodies. This phenomenon was determined to be likely caused by AF3's revolutionary AI model architectures, providing critical insights for future AI design.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>The ability of AlphaFold 3 to efficiently and reliably predict antibody-antigen structures and binding affinities holds substantial clinical impact. It can significantly accelerate the lead identification and optimization phases in the development of novel antibody-based therapeutics, such as CD47-targeting agents for cancer. This could lead to faster and more cost-effective discovery of effective drugs.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The observed "reverse docking" phenomenon in some antibody subjects represents a significant limitation of the current AlphaFold 3 architecture, indicating that its predictions are not universally reliable across all binding scenarios without further refinement. This highlights areas where the AI model's architectural design needs further optimization.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The study suggests future research should focus on optimizing and refining the AI model architectures for structural prediction to address and mitigate issues like "reverse docking." It also implies broader applications for AF3 in predicting various other chemical or physical properties of diverse drug candidates, extending beyond just antibody-antigen binding affinity.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Drug Discovery</span>
                    
                    <span class="tag">Immunotherapy</span>
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Biologics Development</span>
                    
                    <span class="tag">Structural Biology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">AlphaFold 3</span>
                    
                    <span class="tag tag-keyword">Antibody-Antigen</span>
                    
                    <span class="tag tag-keyword">CD47</span>
                    
                    <span class="tag tag-keyword">Binding Affinity</span>
                    
                    <span class="tag tag-keyword">Molecular Docking</span>
                    
                    <span class="tag tag-keyword">Drug Development</span>
                    
                    <span class="tag tag-keyword">Reverse Docking</span>
                    
                    <span class="tag tag-keyword">AI for Structural Prediction</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">AlphaFold 3 (AF3) is a powerful biomolecular structure-predicting tool based on the latest deep learning algorithms and revolutionized AI model architectures. A few of papers have already investigated its accuracy in predicting different biomolecular structures. However, the potential applications of AF3 beyond basic structure prediction have not been fully explored. In our study, we firstly focused on structure predictions of antibody-antigen (CD47) complexes, which is believed to be challenge for AF3 due to limited resolved cognate crystallographic structures. Furtherly, we aimed to the potentiality of AF3 in performing pre-screening for potent antibody candidates as an auxiliary work through binding affinity analysis compared to other molecular docking modules of commercial software, which would greatly benefit the lead identification or optimization process in the drug development. In essence, this is not limited to antibody-antigen binding affinity, but many other chemical or physical properties of any drug candidate based on AF3's accurate predicting structures that are extremely close to the reality. According to our experimental results, AF3 is a very promising competitor, which can efficiently produce highly reliable molecular structures and subsequent binding energy predictions for most subjects. Surprisingly, an unexpected and nonrandom phenomenon "reverse docking" was observed for two of our antibody subjects, suggesting new issues arising from the architectural revolution of AF3. Our analysis and error correction experiments show that this phenomenon is likely to be caused by revolutionized AI model architectures, which provides important experience and reminders for the optimization and design direction of AI for structural prediction. All software copyrights belong to the China Pharmaceutical University (CPU) and its affiliated School of Pharmacy and School of Science.</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>15 pages,4 figures, submitted to ACS Omega</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>